scholarly journals Next-Generation Sequencing of MicroRNAs for Breast Cancer Detection

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Qian Wu ◽  
Zuhong Lu ◽  
Hailing Li ◽  
Jiafeng Lu ◽  
Li Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Ontology ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Target Genes ◽  
Breast Cancer Detection ◽  
Gene Ontology Analysis ◽  
Breast Cancer Patients ◽  
Mirna Profiling ◽  
Serum Mirnas

It is reported that different microRNA (miRNA) profiles can be detected in the blood of cancer patients. We investigated that whether the key serum miRNAs could discriminate patients with and without breast cancer. This study was divided into three parts: (1) miRNA marker discovery using SOLiD sequencing-based miRNA profiling on cancerous and adjacent noncancerous breast tissue of one breast cancer patient; (2) marker selection and validation by real-time PCR on a small set of serum; (3) gene ontology analysis of the key miRNA target genes. Of genome-wide tissue miRNA expression analysis, five miRNAs were found to be altered more than fivefold by SOLiD sequencing (i.e., miR-29a, miR-23a, miR-23b, miR-192, and miR-21). All the five miRNAs were validated on the 20 breast cancer patients and 20 controls. miR-29a and miR-21 were significantly increased in the serum of breast cancer patients (). Gene ontology analysis of the target genes revealed enrichment for special biological process categories, that is, signal transduction, development, apoptosis, cell proliferation, and cell adhesion. SOLiD sequencing provides a promising method for cancer-related miRNA profiling. Serum miRNAs may be useful biomarkers for breast cancer detection.

scholarly journals Breast Cancer Detection from a Urine Sample by Dog Sniffing

2020 ◽  
Author(s):  
Shoko Kure ◽  
Shinya Iida ◽  
Marina Yamada ◽  
Hiroyuki Takei ◽  
Naoyuki Yamashita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Breast Cancer Detection ◽  
Urine Samples ◽  
Malignant Diseases ◽  
Breast Cancer Patients ◽  
Double Blind ◽  
Blind Test ◽  
Detect Breast Cancer

Abstract Background: Breast cancer is a leading cause of cancer death worldwide. Several studies have demonstrated that dog can sniff and detect cancer in the breath or urine sample of a patient. Objective: The aim of this study is to assess whether the trained dog can detect breast cancer from urine samples.Methods: A nine-year-old female Labrador Retriever was trained to identify cancer from urine samples of breast cancer patients. Urine samples from patients histologically diagnosed with primary breast cancer, those with non-breast malignant diseases, and healthy volunteers were obtained, and a double-blind test was performed. Results: 40 patients with breast cancer, 142 patients with non-breast malignant diseases, and 18 healthy volunteers were enrolled, and their urine samples were collected. In 40 times out of 40 runs of a double-blind test, the trained dog could correctly identify urine samples of breast cancer patients. Sensitivity and specificity of this breast cancer detection method using dog sniffing were both 100%.Conclusions: The trained dog in this study could accurately detect breast cancer from urine samples of breast cancer patients. These results indicate the feasibility of a method to detect breast cancer from urine samples using dog sniffing in the diagnosis of breast cancer.

scholarly journals Breast Cancer Detection From a Urine Sample by Dog Sniffing

2020 ◽  
Author(s):  
Shoko Kure ◽  
Shinya Iida ◽  
Marina Yamada ◽  
Hiroyuki Takei ◽  
Naoyuki Yamashita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Breast Cancer Detection ◽  
Urine Samples ◽  
Malignant Diseases ◽  
Breast Cancer Patients ◽  
Double Blind ◽  
Blind Test ◽  
Detect Breast Cancer

Abstract Background: Breast cancer is a leading cause of cancer death worldwide. Several studies have demonstrated that dog can sniff and detect cancer in the breath or urine sample of a patient. Objective: The aim of this study is to assess whether the trained dog can detect breast cancer from urine samples.Methods: A nine-year-old female Labrador Retriever was trained to identify cancer from urine samples of breast cancer patients. Urine samples from patients histologically diagnosed with primary breast cancer, those with non-breast malignant diseases, and healthy volunteers were obtained, and a double-blind test was performed. Results: 40 patients with breast cancer, 142 patients with non-breast malignant diseases, and 18 healthy volunteers were enrolled, and their urine samples were collected. In 40 times out of 40 runs of a double-blind test, the trained dog could correctly identify urine samples of breast cancer patients. Sensitivity and specificity of this breast cancer detection method using dog sniffing were both 100%.Conclusions: The trained dog in this study could accurately detect breast cancer from urine samples of breast cancer patients. These results indicate the feasibility of a method to detect breast cancer from urine samples using dog sniffing in the diagnosis of breast cancer.

scholarly journals The Impact of COVID-19 Pandemic on Gynecological and Breast Cancer Detection Rate: A Tertiary Center Perspective.

2021 ◽  
Author(s):  
Katharina Knoll ◽  
Elisabeth Reiser ◽  
Katharina Leitner ◽  
Johanna Kögl ◽  
Christoph Ebner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Detection Rate ◽  
Cancer Detection Rate ◽  
Breast Cancer Detection ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Tertiary Center ◽  
The Impact

Abstract Purpose: The aim of the present study was to assess the impact of postponed screening examinations and lockdown measures on gynecological and breast cancer detection rate throughout the year 2020 in a gynecological oncological center in Austria.Methods: Data of 889 patients with either newly diagnosed gynecological or breast cancer between January 2019 and December 2020 were collected. Clinical parameters including symptoms, performance status, comorbidities and referral status were compared in patients, who were newly diagnosed with cancer in the period of the first lockdown from March 2020 – April 2020 and the second lockdown from November 2020 – December 2020 and compared to the same period in 2019.Results: Our results showed a strong decline in newly diagnosed cancers during the lockdown periods: -45% in gynecological cancer and -52% in breast cancer compared to the same period in 2019. Compared to the analogue period of 2019, breast cancer patients reported significantly more tumor-associated symptoms (55% versus 31%, p=0.013) during and in between (48% versus 32%, p=0.022) the lockdowns. During the lockdown periods breast cancer patients were diagnosed with a significantly higher tumor-stage (T2-T4; p=0.047).Conclusion: Both lockdowns led to a strong decrease in newly diagnosed gynecological and breast cancers. Treatment delays in potentially curable disease could lead to inferior clinical outcomes, with the risk of missing the optimal treatment window. As the COVID-19 pandemic will be a challenge for some time to come, new strategies in patient care are needed to optimize cancer screening and management during the pandemic.

scholarly journals Breast cancer detection method, diagnostic interval and use of specialized diagnostic assessment units across Ontario, Canada

2018 ◽  
Vol 38 (10) ◽  
pp. 358-367 ◽  
Author(s):  
Li Jiang ◽  
Julie Gilbert ◽  
Hugh Langley ◽  
Rahim Moineddin ◽  
Patti A. Groome
Keyword(s):  
Breast Cancer ◽  
Usual Care ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Detection Method ◽  
Breast Cancer Detection ◽  
Diagnostic Assessment ◽  
Breast Cancer Patients ◽  
Cancer Diagnostic ◽  
Diagnostic Interval

Introduction Breast cancer is detected through screening or through signs and symptoms. In Canada, mammograms for breast cancer screening are offered in organized programs or independently (opportunistic screening). Province of Ontario breast Diagnostic Assessment Units (DAUs) are facility-based programs that provide coordinated breast cancer diagnostic services, as opposed to usual care, in which the primary care provider arranges the tests and consultations. This study describes breast cancer detection method, diagnostic interval and DAU use across Ontario. Methods The study cohort consisted of 6898 women with invasive breast cancer diagnosed in 2011. We used the Ontario Cancer Registry linked to administrative health care databases. We determined the detection method using the Ontario Breast Screening Program (OBSP) data and physician claims. The diagnostic interval was the time between the initial screen, specialist referral or first diagnostic test and the cancer diagnosis. The diagnostic route (whether through DAU or usual care) was determined based on the OBSP records and biopsy or surgery location. We mapped the diagnostic interval and DAU coverage geographically by women’s residence. Results In 2011, 36% of Ontario breast cancer patients were screen-detected, with a 48% rate among those aged 50 to 69. The provincial median diagnostic interval was 32 days, with county medians ranging from 15 to 65 days. Provincially, 48.4% were diagnosed at a DAU, and this ranged from zero to 100% across counties. Conclusion The screening detection rate in age-eligible breast cancer patients was lower than published population-wide screening rates. Geographic mapping of the diagnostic interval and DAU use reveals regional variations in cancer diagnostic care that need to be addressed.

scholarly journals Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers

2013 ◽  
Vol 34 (3) ◽  
pp. 163-169 ◽  
Author(s):  
Fermín Mar-Aguilar ◽  
Jorge A. Mendoza-Ramírez ◽  
Ismael Malagón-Santiago ◽  
Perla K. Espino-Silva ◽  
Sandra K. Santuario-Facio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Sensitivity And Specificity ◽  
Cancer Detection ◽  
Roc Curve ◽  
Expression Patterns ◽  
Circulating Microrna ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Mirna Profiling

MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that can regulate gene expression, thereby affecting crucial processes in cancer development. miRNAs offer great potential as biomarkers for cancer detection because of their remarkable stability in blood and their characteristic expression in different diseases. We investigated whether quantitative RT-PCR miRNA profiling on serum could discriminate between breast cancer patients and healthy controls. We performed miRNA profiling on serum from breast cancer patients, followed by construction of ROC (Receiver Operating Characteristic) curves to determine the sensitivity and specificity of the assay. We found that seven miRNAs (miR-10b, miR-21, miR-125b, miR-145, miR-155 miR-191 and miR-382) had different expression patterns in serum of breast cancer patients compared to healthy controls. ROC curve analyses revealed that three serum miRNAs could be valuable biomarkers for distinguishing BC from normal controls. Additionally, a combination of ROC curve analyses of miR-145, miR-155 and miR-382 showed better sensitivity and specificity of our assay. miRNA profiling in serum has potential as a novel method for breast cancer detection in the Mexican population.

scholarly journals Dysregulation of miR-638 in Breast Cancer Patients and Bioinformatics Investigation of Its Target Genes in Apoptosis, Angiogenesis and Autophagy Pathways

2019 ◽  
Vol 12 (11) ◽  
Author(s):  
Samaneh Ahmadi ◽  
Mojtaba Saffari ◽  
Mohammad Hossein Modarressi ◽  
Reza Shirkoohi ◽  
Marjan Jamalian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Target Genes ◽  
Breast Cancer Patients

scholarly journals Multilectin Affinity Chromatography for Characterization of Multiple Glycoprotein Biomarker Candidates in Serum from Breast Cancer Patients

2006 ◽  
Vol 52 (10) ◽  
pp. 1897-1905 ◽  
Author(s):  
Ziping Yang ◽  
Lyndsay E Harris ◽  
Darryl E Palmer-Toy ◽  
William S Hancock
Keyword(s):  
Breast Cancer ◽  
Gene Ontology ◽  
Affinity Chromatography ◽  
Cancer Patients ◽  
Dynamic Range ◽  
Ion Homeostasis ◽  
Internal Standard ◽  
Breast Cancer Patients ◽  
Protease Inhibition ◽  
Large Panels

Abstract Background: Glycoproteins are often associated with cancer and are important in serum studies, for which glycosylation is a common posttranslational modification. Methods: We used multilectin affinity chromatography (M-LAC) to isolate glycoproteins from the sera of breast cancer patients and controls. The proteins were identified by HPLC–tandem mass spectrometry (MS/MS) analysis of the corresponding tryptic digests. We used the FuncAssociate Gene Ontology program for association analysis of the identified proteins. Biomarker candidates in these groups were comparatively quantitated by use of peak area measurements, with inclusion of an internal standard. We analyzed data for concordance within the ontology association groups for vector of change with the development of breast cancer. Results: Detection of the known low-concentration biomarker HER-2 (8–24 μg/L) enabled us to establish a dynamic range of 106, relative to the amount of albumin, for the depletion step. We then used ELISA to confirm this range. Proteins associated with lipid transport and metabolism, cell growth and maintenance, ion homeostasis, and protease inhibition were found to be differentially regulated in serum from women with breast cancer compared with serum from women without breast cancer. Conclusions: M-LAC for isolation of the serum glycoproteome, coupled with liquid chromatography–MS/MS and the use of gene ontology associations, can be used to characterize large panels of candidate markers, which can then be evaluated in a particular patient population.

EXPERIMENTAL STUDY ON RADAR-BASED BREAST CANCER DETECTION USING UWB ANTENNAS WITHOUT BACKGROUND SUBTRACTION

2011 ◽  
Vol 23 (05) ◽  
pp. 383-391 ◽  
Author(s):  
Dan Zhang ◽  
Atsushi Mase
Keyword(s):  
Breast Cancer ◽  
Cancer Detection ◽  
Background Subtraction ◽  
Breast Cancer Detection ◽  
Ultra Wideband ◽  
Breast Cancer Patients ◽  
Uwb Antennas ◽  
Pulse Radar ◽  
Reflection Data ◽  
Cancer Tumor

An ultrashort-pulse radar using ultra-wideband (UWB) antennas such as compact Vivaldi antennas has been applied to the simulation experiment of breast cancer detection. A cooking-oil model and a commercial-made synthetic breast phantom model, which have been developed, as well as with real breast cancer patients during initial clinical trials have been used in our experiment. We detect the breast cancer tumor without using the background subtraction method. Image reconstructions of the breast models using reflection data have been performed by use of confocal microwave imaging (CMI) technique.

scholarly journals The target E2F family gene PTTG1 for prediction of distant relapse-free survival in breast cancer patients receiving taxane and anthracycline-based NACT

2021 ◽  
Author(s):  
Yuhao Xu ◽  
Yaoqiang Du ◽  
Qinghui Zheng ◽  
Hongchao Tang ◽  
Yangyang Qian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Target Genes ◽  
Cox Regression ◽  
Gene Expression Omnibus ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Distant Relapse ◽  
Potential Biomarker

Abstract Background Recent years, the breast cancer became the most commonly diagnosed cancer. The use of neoadjuvant chemotherapy (NACT) makes a significant contribution to chemotherapy in breast cancer. We aimed to develop the novel model as a predictor of distant relapse-free survival (DRFS) in breast cancer patients receiving taxane and anthracycline-based NACT. Methods We collected the mRNA expression datasets of patients from GSE25055 and GSE25065 in Gene Expression Omnibus (GEO). Univariate and Multivariate Cox Regression Analyses were conducted to achieve the prognostic genes that associated with DRFS. Moreover, the E2F targets genes were obtained from GSEA. We obtained the intersection genes between the prognostic genes and E2F target genes, then validated in GSE32603 dataset. And we established a nomogram model based on PTTG1 expression level and several clinical characteristics. Results A novel nomogram was conducted. The receiver operating characteristic (AUC = 0.849), C-index (0.805) and calibration plots were applied to assess the effect of this model. Conclusion Our study found that the E2F target genes, such as the PTTG1 may serve as a potential biomarker in breast cancer, and provided superior estimation of DRFS, which can guide the clinical practice in NACT of breast cancer.

Detection rate is not higher for women with BBD history in breast cancer screening

2019 ◽  
Author(s):  
Penghuan Qu ◽  
Xueou Liu ◽  
Yubei Huang ◽  
Ziwei Feng ◽  
Xin Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Detection ◽  
Detection Rate ◽  
Breast Disease ◽  
Cancer Detection Rate ◽  
Breast Cancer Detection ◽  
Breast Cancer Patients ◽  
Contrast Analysis

Abstract Background To investigate whether women with benign breast disease (BBD) history have higher breast cancer detection rate in screening. Methods We reviewed data for 33 001 female participants in Multi-modality Independent Screening Trial (MIST). Corresponding data for 6823 breast cancer patients were retrieved from the Tianjin Breast Cancer Cases Cohort (TBCCC) and analyzed for comparison. Results The breast cancer detection rate was 2.83‰ among women with BBD history and 3.28‰ in women without. Moreover, the proportion of carcinoma in situ (CIS) was also lower in women with BBD history than women without (7.69 versus 20.31%). In contrast, analysis of TBCCC data revealed a higher proportion of CIS in patients with BBD history (5.05%) than patients without (3.26%). Our data showed that a larger proportion of women with BBD history had undergone previous breast examinations. Additionally, among participants diagnosed with both breast cancer and BBD in MIST, we found a lower proportion of CIS in women with BBD history (11.76%) compared to women without (32.14%). Conclusions Women with BBD history were not found to have higher detection rate in breast cancer screening. Women with BBD history were more likely to be proactive in seeking breast examinations and to have breast cancer be diagnosed in clinic.

Sign in / Sign up

Export Citation Format

Share Document